Showing results (181-190 of 305) with videos related to

Sort By:
Pageof 31
Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.
Stem Cell Research & Therapy|April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party studyPellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Leukemia|June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
European Journal of Haematology|November 26, 2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMAFortunato Morabito, Massimo Gentile, Stefania Ciolli, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
Advances in Therapy|January 21, 2021
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab MonotherapyAjai Chari, Markus Munder, Katja Weisel, et al.
Blood|April 15, 2011
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myelomaLuisa Giaccone, Barry Storer, Francesca Patriarca, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Pageof 31